 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today announced NKX019 and NKX101 clinical development program updates. 